EcoR1 Capital, LLC Buys Arvinas Inc, Assembly Biosciences Inc, Morphic Holding Inc, Sells Spark Therapeutics Inc, argenx SE, Solid Biosciences Inc

• New Purchases: ARVN, MORF, ANAB, IDDA, ACAD, SAGE, SELB, PIRS, FATE, EOLS, SVRA, IOVA, XFOR, CRVS, ACRS, CTMX, UROV,
• Added Positions: ASMB, MRUS, NLTX, RARE, FGEN, CYCN, MRTX, KURA, RUBY,
• Reduced Positions: ARGX, HARP, EIGR, XCUR, DRNA, IRWD, PRVL, SURF, RCUS,
• Sold Out: ONCE, SLDB, SRPT, NXTC, CRIS, ZFGN, AUTL, RGLS, UBX,

For the details of EcoR1 Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/ecor1+capital%2C+llc/current-portfolio/portfolio

1. Prothena Corp PLC (PRTA) - 9,426,640 shares, 13.83% of the total portfolio.
2. Xencor Inc (XNCR) - 2,501,557 shares, 7.97% of the total portfolio.
3. Dicerna Pharmaceuticals Inc (DRNA) - 3,627,597 shares, 7.40% of the total portfolio. Shares reduced by 8.46%
4. FibroGen Inc (FGEN) - 1,492,221 shares, 5.93% of the total portfolio. Shares added by 15.34%
5. Kura Oncology Inc (KURA) - 4,241,953 shares, 5.40% of the total portfolio. Shares added by 4.95%

EcoR1 Capital, LLC initiated holding in Arvinas Inc. The purchase prices were between $15.39 and $44.38, with an estimated average price of $29.74. The stock is now traded at around $49.92. The impact to a portfolio due to this purchase was 5.1%. The holding were 1,339,069 shares as of .

EcoR1 Capital, LLC initiated holding in Morphic Holding Inc. The purchase prices were between $13.02 and $19.5, with an estimated average price of $15.61. The stock is now traded at around $15.42. The impact to a portfolio due to this purchase was 3.43%. The holding were 2,154,845 shares as of .

EcoR1 Capital, LLC initiated holding in AnaptysBio Inc. The purchase prices were between $10.18 and $38.96, with an estimated average price of $23.27. The stock is now traded at around $15.77. The impact to a portfolio due to this purchase was 2.96%. The holding were 1,966,100 shares as of .

EcoR1 Capital, LLC initiated holding in Innate Pharma SA. The purchase prices were between $4.84 and $5.7, with an estimated average price of $5.32. The stock is now traded at around $6.50. The impact to a portfolio due to this purchase was 2.71%. The holding were 4,545,454 shares as of .

EcoR1 Capital, LLC initiated holding in ACADIA Pharmaceuticals Inc. The purchase prices were between $37.4 and $51.4, with an estimated average price of $43.7. The stock is now traded at around $45.44. The impact to a portfolio due to this purchase was 1.98%. The holding were 500,000 shares as of .

EcoR1 Capital, LLC initiated holding in Sage Therapeutics Inc. The purchase prices were between $60.18 and $154.77, with an estimated average price of $122.53. The stock is now traded at around $68.61. The impact to a portfolio due to this purchase was 1.16%. The holding were 173,364 shares as of .

EcoR1 Capital, LLC added to a holding in Assembly Biosciences Inc by 2372.33%. The purchase prices were between $8.36 and $23.81, with an estimated average price of $15.55. The stock is now traded at around $20.95. The impact to a portfolio due to this purchase was 4.35%. The holding were 2,388,268 shares as of .

EcoR1 Capital, LLC added to a holding in Merus NV by 937.56%. The purchase prices were between $14.08 and $18.5, with an estimated average price of $16.06. The stock is now traded at around $19.15. The impact to a portfolio due to this purchase was 2.02%. The holding were 1,718,200 shares as of .

EcoR1 Capital, LLC added to a holding in Neoleukin Therapeutics Inc by 72.82%. The purchase prices were between $2.65 and $12.72, with an estimated average price of $5.14. The stock is now traded at around $11.11. The impact to a portfolio due to this purchase was 1.88%. The holding were 3,915,880 shares as of .

EcoR1 Capital, LLC added to a holding in Ultragenyx Pharmaceutical Inc by 324.92%. The purchase prices were between $36.08 and $45.83, with an estimated average price of $41.28. The stock is now traded at around $61.10. The impact to a portfolio due to this purchase was 0.8%. The holding were 261,554 shares as of .

EcoR1 Capital, LLC added to a holding in Cyclerion Therapeutics Inc by 133.31%. The purchase prices were between $1.8 and $13.43, with an estimated average price of $4.51. The stock is now traded at around $4.04. The impact to a portfolio due to this purchase was 0.26%. The holding were 1,811,000 shares as of .

EcoR1 Capital, LLC added to a holding in Mirati Therapeutics Inc by 46.99%. The purchase prices were between $70.76 and $128.86, with an estimated average price of $97.36. The stock is now traded at around $96.72. The impact to a portfolio due to this purchase was 0.25%. The holding were 65,000 shares as of .

EcoR1 Capital, LLC sold out a holding in Spark Therapeutics Inc. The sale prices were between $96.25 and $113.57, with an estimated average price of $107.51.

EcoR1 Capital, LLC sold out a holding in Solid Biosciences Inc. The sale prices were between $2.82 and $12.9, with an estimated average price of $7.22.

EcoR1 Capital, LLC sold out a holding in Sarepta Therapeutics Inc. The sale prices were between $77.69 and $135.58, with an estimated average price of $101.97.

EcoR1 Capital, LLC sold out a holding in NextCure Inc. The sale prices were between $25 and $92.22, with an estimated average price of $42.28.

EcoR1 Capital, LLC sold out a holding in Curis Inc. The sale prices were between $1.36 and $2.44, with an estimated average price of $1.81.

EcoR1 Capital, LLC sold out a holding in Zafgen Inc. The sale prices were between $0.7 and $1.25, with an estimated average price of $0.8.